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Abstract

Psoriasis is a chronic, immune-mediated disorder characterized by well
demarcated, erythematous plaques covered by thick, silvery-white scales, most
often located on the knees, elbows, sacral area and scalp. It has a significant impact
on the patient's quality of life.
Biological therapies revolutionized the treatment of psoriasis vulgaris but there
has been concern regarding the use of those agents due to severe adverse reactions
reported in patients receiving TNF-α inhibitors for various inflammatory diseases.
The aim of this paper is to review the most important adverse reactions
reported in patients receiving biological treatments. The most common and severe
side effects associated with biologicals are infections, cardiac adverse reactions,
neurologic adverse reactions, lymphomas, non-melanoma skin cancers and
hepatobiliary disease.
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Introduction

patients

Psoriasis is a chronic, immune-mediated disorder
characterized by well demarcated, erythematous plaques
covered by thick, silvery-white scales, most often
located on the knees, elbows, sacral area and scalp. Any
region however can be involved. It has a worldwide
distribution and a prevalence of approximately 2%. It
can occur at any age but it presents two peaks of onset:
one at 20-30 years and the second at 50-60 years.
Psoriasis has a significant impact on the patient's quality
of life. Several topical and systemic therapies are
available nowadays for the treatment of psoriasis.
Topical treatments are difficult to apply and timeconsuming.

Systemic

conventional

therapies

are

associated with severe adverse reactions. As a result,
patient's compliance and adherence to treatment are low
Biological therapies revolutionized the treatment of
psoriasis vulgaris. In Romania, they are recommended
for patients with moderate to severe plaque type
psoriasis unresponsive or intolerant to conventional
therapies. Three biologicals have been largely used so
far: infliximab, adalimumab and etanercept. All of those
are antibodies directed against tumor necrosis factor-α
(TNF-α). In years recent, experience with ustekinumab,
human

monoclonal

antibody

directed

against

interleukin (IL) 12 and 23, has also increased. Despite
the

etanercept.

They

are

mainly

represented by erythema, edema, pruritus, hemorrhages,
ecchymosis and low to moderate pain. The higher
incidence of local adverse reactions in patients receiving
etanercept is due to the more frequent administration of
the drug. Injection site reactions are generally well
tolerated and do not usually require interrupting the
treatment. Topical corticosteroids and antalgics are
sometimes useful. Varying the injection site is
recommended (5, 6).
Infusion

reactions

have

been

reported

in

approximately 17% of patients receiving infliximab and
headache, dizziness, nausea, fever and pruritus are the
most frequent symptoms. Life threatening adverse
reactions such as convulsions and anaphylactic shock
have been reported in approximately 0.5% of patients
receiving infliximab. Infusion reactions can be acute or

(1-3).

a

receiving

very good

results

obtained

with

biological

treatments, the clinician and the patient should be aware
of possible adverse reactions (4).

delayed. Acute reactions occur during the first hour and
are represented by hives, rash, fever, bronchospasm,
laryngopharyngeal edema, dyspnea and hypotension.
Most cases only require decreasing the infusion rhythm
or temporarily ceasing the infusion. Severe cases
however
stabilizing

necessitate
the

stopping

patient.

the

Delayed

treatment

and

hypersensitivity

reactions are represented by myalgia, arthralgia, fever,
headaches, rash, fatigability and facial edema (5, 7).
Infections
Tuberculosis is one of the most important adverse
events associated with biological therapies. Those can
determine the reactivation of a latent tuberculosis or de
novo infection. The risk of extrapulmonary tuberculosis

Discussion


is also higher in these patients. Given the high incidence

Adverse events in patients receiving biological of this infection in the general population, testing all
therapies

patients prior to starting biological treatment is

Local adverse reactions

mandatory (8).

Injection site reactions are the most frequently

A study performed in Sweden by Asklinget al.

reported adverse events and occur in approximately assessed the risk of developing tuberculosis of patients
17.5% of patients treated with adalimumab and 22.4% of receiving TNF-α inhibitors and compared it to the risk
5
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encountered in the general population. According to the with biological agents. The most common opportunistic
authors, patients receiving biological therapies have a 4 infections were listeriosis, nocardiosis, infections with
fold higher risk of developing tuberculosis than patients atypical
who do not receive biological treatment (9).

mycobacteria,

pneumocystosis,

Singh et al. conducted a meta-analysis of studies leishmaniosis

atypical

aspergillosis,
and

disseminated

salmonellosis,
cryptococcosis,
cytomegalovirus

performed on patients receiving biological therapies. The infection. Infliximab was associated with the highest risk
authors included 163 randomized controlled studies with of developing opportunistic infections while etanercept
50,010 participants and 46 extension studies with 11 954 was associated with the lowest risk (13).
participants. The authors showed that patients treated

Lanternier et al. performed a prospective study

with TNF-α inhibitors had a higher risk of developing between 2004 and 2007 in which they described the
tuberculosis than patients in the control group (10).

incidence of Legionella pneumophilapneumonia in

Cutaneous infections like cellulitis, erysipelas or patients treated with biological agents. The authors
abscess have been reported in 0.1-7% of patients treated reported an annual incidence of 46.7 cases/100,000
with biological therapies. Superficial fungal infections of patient-years and concluded that the incidence of
the skin are also more frequent in patients receiving Legionella pneumophila pneumonia is high in patients
biologicals. Some cases of disseminated herpes simplex receiving biological therapies, especially infliximab and
virus infection and reactivation of the varicella-zoster adalimumab (14).
virus have also been reported. Strangfeldet al. performed

Wissman et al. examined the pharyngeal exudate

a study in which they included 5,040 patients with from 125 patients with rheumatological disorders, half of
rheumatoid arthritis who were treated with TNF-α those being treated with infliximab. The authors
inhibitors or with disease-modifying antirheumatic drugs demonstrated Pneumocystis jirovecii colonization in
(DMARDs). The authors observed that the risk of 25.6% of patients and concluded that infliximab
developing herpes zoster was high in patients receiving treatment is an important risk factor for developing this
adalimumab and infliximab but not in patients receiving infection (15).
etanercept (11). Mc Donald et al. performed a

Invasive fungal infections were reported in patients

retrospective study in which they included 20,357 receiving TNF-α inhibitors. Tsiodras et al. performed a
patients treated for rheumatoid arthritis between 1998 literature review and identified 281 cases of invasive
and 2005 and found that the risk of developing herpes fungal infections in patients treated with biological
virus is higher in patients treated with biological agents. 80% of those occurred in patients treated with
treatments, patients receiving infliximab having the infliximab, 16% in patients treated with etanercept and
highest risk (12).

4% in patients receiving adalimumab (16).

Opportunistic infections have been reported in
patients receiving TNF-α inhibitors. Salmon-Ceron et al.

Cardiovascular adverse reactions
Various cardiovascular adverse events have been

performed a prospective study in which they aimed to associated with biological therapies. Heart failure is one
describe

opportunistic

infections,

other

than of the most important adverse reactions reported in the

tuberculosis, in patients with rheumatoid arthritis, medical literature. Setoguchi et al. showed in a study
inflammatory colitis, psoriasis vulgaris, ankylosing performed between 1994 and 2004, which included 1002
spondylitis and other inflammatory conditions treated patients treated with TNF-α inhibitors and 5593 patients
6
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treated with methotrexate for rheumatoid arthritis, that

Development of anti-drug antibodies

patients receiving biological agents had a higher risk to

Biological therapies act as antigens after they are

develop cardiac insufficiency than patients treated with administered because of their protein structure. As a
methotrexate (17). Curtis et al on the other hand result, the immune system can create antibodies directed
performed a study in which they included young patients against them. The development of anti-drug antibodies
suffering from rheumatoid arthritis or Crohn's disease was reported for all biological therapies. Two main types
who received biological treatment or other treatments of anti-drug antibodies were described in the medical
and noticed no significant difference regarding the rate literature: neutralizing antibodies, which decrease or
of heart failure between patients receiving anti-TNF-α even annul the effect of the biological agent, and nonagents and patients receiving other treatments (18). neutralizing antibodies, which do not influence the
Other authors, like Wolfe and Michaud, showed that pharmacological proprieties of the drug (2, 23).
biological therapies decrease the risk of cardiac

Infliximab is a chimeric mouse-human monoclonal

insufficiency. The two scientists reached this conclusion antibody and its administration is frequently associated
after analyzing data from 13,171 patients with with the development of anti-drug antibodies which are
rheumatoid

arthritis

and

2,568

patients

with generally neutralizing. Adalimumab is a fully human

osteoarthritis (19).

monoclonal antibody. For that reason, it was initially

Arrhythmias were also reported in patients receiving believed that it would not be recognized as non-self by
infliximab. Lazzerini et al. performed a prospective the immune system. Recent studies however contradict
placebo controlled study in which they included patients this idea, as neutralizing antibodies directed against
with ankylosing spondylitis and rheumatoid arthritis who adalimumab were detected. Etanercept is a fusion
were monitored during the infliximab infusion or protein produced by recombinant DNA technology.
placebo infusion, respectively. The authors showed that Anti-drug antibodies were described in patients treated
tachyarrhythmia and bradyarrhythmia were present in with etanercept but these antibodies are not neutralizing
both examined groups and the difference was not

(2).
A study performed by Van Schie et al. showed that

statistically significant (20).

Data regarding the effect of biological therapies on more than 90% of the antibodies directed against
the vascular system is contradictory. Some authors adalimumab and infliximab are neutralizing as they
consider that they might improve endothelial function interact with the portion responsible for binding TNF-α.
and reduce the rate of cardiovascular events while others The rest of the antibodies are non-neutralizing as they
consider that long-time treatment with infliximab is bind to other portions of the antibodies, which are not
proatherogenic (21).

involved in binding TNF-α (24).

Cardiac output also seems to be decreased in patients

Kui et al. showed in a study performed on patients

treated with infliximab. Santos et al. performed a study with psoriasis treated with TNF-α inhibitors that the
in which they included 14 patients with rheumatoid presence of anti-drug antibodies is associated with
arthritis with no history of cardiac insufficiency and higher severity of psoriasis and lower serum levels of
measured a significant reduction of the cardiac output TNF-α inhibitors (25). Murdaca et al. also showed that
and stroke volume during the infliximab infusion (22).

the

presence

of

neutralizing

antibodies

against
7
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adalimumab and infliximab decreases the chances of however is comparable to that found in the general
obtaining clinical remission of the disease, decreases the population (29-31).
drug survival duration and increases the necessity to

Non-melanoma skin cancers

administer higher doses of biological agent (26).

TNF-α inhibitors are associated with higher rates of

The concomitant administration of biological agents skin cancers, especially non-melanoma skin cancers.
with methotrexate and other immunosuppressives Askling et al. performed a meta-analysis in 2011 in
decreases the risk of developing anti-drug antibodies.
Data regarding their usefulness in patients with psoriasis
is contradictory and additional studies are needed to
support the efficiency of the combined treatment (27).
Neurological adverse events
The

most

important

which they included 74 randomized controlled studies
which evaluated the short term risk of developing skin
cancers. 15,418 patients were randomized to the group
treated with TNF-α inhibitors and 7,486 patients were
randomized to the control group. The authors concluded
that patients receiving biological agents have a short

neurological

side-effects term risk of 2.02% of developing non-melanoma skin
associated with biological therapies are demyelinating cancer (32).
diseases of the central nervous system, optic neuritis,

The concomitant or previous administration of other

facial paresis, peripheral neuropathy, transverse myelitis, treatments such as methotrexate, cyclosporine or PUVA
Guillain-Barré syndrome and infectious diseases (28, can increase the incidence of non-melanoma skin
29).

cancers in patients treated with biological agents. Those
Progressive multifocal leukoencephalopathy (PML), patients must therefore avoid sun exposure and be

a potentially fatal infectious disease determined by closely monitored for early detection of skin cancers (5).
Lymphomas
activation of the John Cunningham virus, was reported
after the treatment with monoclonal antibodies, such as
infliximab,

adalimumab,

etanercept,

efalizumab,

rituximab, etc. John Cunningham virus is a double
stranded DNA polyomavirus. It is an ubiquitous
neurotropic virus. Studies indicate that 50-90% of adults
have been exposed to it. PML was initially described as
a complication of chemotherapy in hematological

The occurrence of lymphomas has been described in
patients

receiving

TNF-α

inhibitors

for

various

disorders. Until now, however, it has been impossible to
say if biological therapies truly increase the risk of
developing lymphomas as data from the specialty
literature is contradictory. Some studies concluded that
patients treated with adalimumab and infliximab have a
higher risk of developing lymphomas than patients

patients. Nowadays, it is considered an important

treated with etanercept. Other studies did not find higher
complication of HIV infection. If patients remain risk of developing lymphomas in patients treated with
immunosuppressed, they die within months. Efalizumab biological agents. It is worth mentioning that most
was voluntarily pulled off the market after three patients studies assessing the risk of lymphoma were performed
with psoriasis died from PML, as it was considered that on patients with rheumatoid arthritis. Rheumatoid
the benefits do not outweigh the risk. Cases of PML arthritis itself is associated with a higher risk of
have also been reported in patients receiving infliximab, developing lymphoma. Even though the risk of
adalimumab and etanercept. The incidence of the disease lymphoma does not seem to be higher in patients treated

8
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with biological agents, continued vigilance is warranted treatments. Some authors therefore suggested that safety
(33, 34).
Hepatic adverse reactions

data from other inflammatory disorders should not be
applied to patients with psoriasis. To support this idea,

Autoimmune hepatitis, jaundice and drug-induced Garcia-Doval et al. compared data from two national
hepatic dysfunction can all be associated with the use of drug safety registers: Biobadaser, the registry for
biological therapies. The administration of TNF-α rheumatic diseases and Biobadaderm, the registry for
inhibitors in patients with hepatitis B and hepatitis C is psoriasis. The authors showed that the risk of serious
not an absolute contraindication. The clinician however adverse events is almost two fold higher in patients with
must carefully assess the risk/benefit ratio before rheumatoid arthritis than in patients with psoriasis
recommending these treatments to patients with hepatic treated with anti-TNFα inhibitors. The authors also
disorders. Reactivation of hepatitis B in HBsAg carriers showed that patients receiving biological therapies for
was reported after the administration of biological rheumatoid arthritis have a higher risk of developing
agents. TNF-α plays an important role in the eradication infections, cardiac disorders, respiratory disorders, and
of hepatitis B virus. Perez et al. performed a review of infusion related reactions while patients receiving
the literature and noticed a 39% increase in the biologicals for psoriasis have a higher risk of developing
reactivation rate of HBV in HBsAg carriers treated with skin and subcutaneous tissue disorders and hepatobiliary
anti-TNF-α agents. The risk seems to be higher in diseases (40).
patients treated with infliximab (35, 36).

A study which included 173 psoriasis patients who

TNF-α inhibitors seem to be safe in patients with were prospectively followed for 5 years also showed that
hepatitis C. Studies show that TNF-α level is high in long-term treatment with biologicals is safe in this group
patients with hepatitis C and is associated with high of patients, the rate of malignancies, serious infections
levels of serum transaminases, histological changes and and serious cardiovascular events being comparable with
fibrosis. A study which included 216 patients with the general population incidence rate. The authors also
hepatitis C treated with TNF-α inhibitors showed that found that psoriatic patients treated with anti-TNF-α
only 3 patients required terminating treatment due to agents

have

a

higher risk of

developing skin

hepatitis C reactivation. The viral load remains constant malignancies, probably due to previous exposure to UVor even decreases after short term treatment with therapies and immunosuppressive drugs, but also
biological agents (37, 38). However, some cases of because these patients are more closely followed by
hepatocellular carcinoma were reported in patients with dermatologists (41).
HCV who received long term treatment for psoriasis
vulgaris. Regular follow-ups are therefore mandatory in
those patients (38, 39).


Conclusions
Psoriasis vulgaris is a chronic, inflammatory disease

Should safety data from other inflammatory with a great impact on the patient's quality of life. TNF-α
disorders be extrapolated to psoriasis?

inhibitors have revolutionized the treatment of psoriasis

Most data regarding the safety of biological therapies but there has been some concern regarding the use of
comes from patients treated for rheumatic diseases and those agents due to severe adverse reactions reported in
from inflammatory bowel disease. These disorders are patients receiving biological therapies for various
associated with comorbidities and require specific inflammatory diseases. The most important severe
9
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adverse reactions associated with biologicals are 8. Fleischmann R, Yocum D. Does safety make a
infections, cardiac adverse reactions, neurologic adverse

difference in selecting the right TNF antagonist?

reactions, lymphomas, non-melanoma skin cancers and

Arthritis Res Ther. 2004; 6(2): S12.

hepatobiliary disease. Most adverse events were reported 9. Askling J, Fored CM, Brandt L, Baecklund E,
in patients receiving anti-TNFα agents for rheumatic

Bertilsson L, Cöster L, Geborek P, Jacobsson LT,

diseases and the safety data were extrapolated to

Lindblad S, Lysholm J, Rantapää‐Dahlqvist S. Risk

psoriatic patients. New studies performed on psoriatic

and

patients treated with biological agents are therefore

rheumatoid arthritis associated with tumor necrosis

required in order to establish the safety profile of the

factor antagonists in Sweden. Arthritis Rheum 2005;

drugs in this particular group.

52(7): 1986-92.
10. Singh
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